Keros Therapeutics (KROS) Current Deferred Revenue (2025)

Keros Therapeutics (KROS) posted Current Deferred Revenue of $155000.0 for Q3 2025, down 83.24% on a QoQ basis from $925000.0 in Q2 2025.

Keros Therapeutics (KROS) Current Deferred Revenue (2025) Analysis & Trends

Keros Therapeutics' Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $155000.0 for Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Keros Therapeutics	377.42 Mn	90.02 Mn	-

Download Data